Ann: Appendix 4C - quarterly , page-2

I like the bit about highest ever quarter for FerriScan. With their clients increasing worldwide hopefully the income will start to snowball.
If the US hospitals FerriScan funding from state based Medicaid insurance schemes grows across the US then we could expect a large increase in scan numbers.
Hopefully we can break this downtrend, IMO our mc is very low considering what the company is acheiving and our collaberations with Novartis and Pfizer.
With 360 million shares on issue it seems strange that the liquidity of this stock is so low. Does anyone have alist of the top 20 or a reason for the low volumes ?

Cheers
ACM1




"Cash receipts from customers increased 27% compared to the prior quarter, partly due to the timing of
receipt of payments from customers but also reflecting the highest ever quarter for FerriScan volumes,
up 18% on the corresponding quarter last year.
Revenue grew by 12% compared to the same quarter in the preceding year. The strong Australian
dollar continues to have a negative impact on revenue. The Company has submitted an FDA
application for its cardiac iron test providing an opportunity to further increase revenue from the iron
overload market where the Company has an established customer base.
Resonance Health continues to work towards gaining access to insurance funding for FerriScan from
private and public insurance payers. Some US hospitals are now gaining FerriScan funding through
the state based Medicaid insurance scheme and the Company is working to formalise the Medicaid
coverage for FerriScan in states with a high prevalence of iron overload."